NICE建议英格兰为更年期热闪电提供非激素药物Veoza,帮助大约500万不能使用HRT的妇女。 NICE recommends non-hormonal drug Veoza for menopausal hot flashes in England, aiding ~500K women unable to use HRT.

英国国家卫生和护理卓越研究所 (NICE) 建议以Veoza的名称销售的fezolinetant,用于英国的NHS治疗不能使用激素替代疗法的女性中度至严重的更年期热和夜间出汗. The UK’s National Institute for Health and Care Excellence (NICE) has recommended fezolinetant, sold as Veoza, for use on the NHS in England to treat moderate to severe menopausal hot flushes and night sweats in women who cannot use hormone replacement therapy. 每天的非激素避孕药通过堵住与这些症状有关的大脑途径发挥作用,为大约500 000名妇女提供了救济。 The daily non-hormonal pill works by blocking brain pathways linked to these symptoms, offering relief for an estimated 500,000 women. 根据其有效性和成本效益核准治疗,目的是改善睡眠、集中和总体生活质量。 Approved based on its effectiveness and cost-efficiency, the treatment aims to improve sleep, concentration, and overall quality of life. 虽然该决定适用于英格兰、威尔士和北爱尔兰,但预计将遵循国家儿童教育委员会的指导,苏格兰将独立决定。 While the decision applies to England, Wales and Northern Ireland are expected to follow NICE guidance, while Scotland will decide independently. 这一转变标志着为寻求HRT替代方案的妇女提供治疗选择的显著扩展。 The move marks a significant expansion of treatment options for women seeking alternatives to HRT.